Halozyme Therapeutics, Inc., a biotechnology company, announced that in December 2025 it entered into a global collaboration and exclusive license agreement with Takeda. The agreement grants Takeda access to Halozyme’s ENHANZE technology, which uses the proprietary recombinant human hyaluronidase PH20 enzyme, for use with vedolizumab, marketed globally as ENTYVIO.

Health Technology Insights: OsteoCentric Technologies Appoints Matthew Collier to Board of Directors

Dr. Helen Torley, President and Chief Executive Officer of Halozyme, said that the collaboration demonstrates Halozyme’s commitment to providing innovative solutions that improve the patient experience. She added that the partnership highlights the broad potential of ENHANZE technology across multiple therapeutic areas and its ability to simplify treatment for patients. Robert Hollowell, M.D., Head of Global Product and Launch Strategy for GI and Inflammation at Takeda, noted that flexible treatment options are essential for people living with ulcerative colitis and Crohn’s disease. He said the collaboration reflects Takeda’s commitment to the IBD community and could allow more patients worldwide to benefit from vedolizumab while making therapy easier to integrate into daily life.

Health Technology Insights: Samsung Biologics Acquires Human Genome Sciences from GSK

Under the terms of the agreement, Takeda will make an upfront payment to Halozyme along with potential future development and commercial milestone payments. Halozyme will also receive up to low- to mid-single-digit royalties on sales of products that combine vedolizumab with ENHANZE.

Crohn’s disease and ulcerative colitis are the main forms of inflammatory bowel disease, which cause chronic gastrointestinal inflammation and can lead to serious complications. Global prevalence of IBD is expected to exceed 10 million people within the next ten years, highlighting the growing healthcare burden. Vedolizumab, sold as ENTYVIO, is approved for intravenous and subcutaneous administration depending on the market, and is indicated for adults with moderately to severely active Crohn’s disease or ulcerative colitis.

Health Technology Insights: SCIENTURE Launches FDA-Approved High-Strength REZENOPY

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com